CME vs Tradeweb Markets
CME and TW side by side, both in security & commodity brokers, dealers, exchanges & services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CME and TW compare
CME is the larger company, worth 3.8 times as much as Tradeweb Markets ($109B against $28.7B).
On earnings, CME is cheaper: it trades at 25.7× trailing earnings, against 28.8× for Tradeweb Markets.
Tradeweb Markets grew revenue faster over the last twelve months (14.4% versus 5.1% for CME).
Both pay dividends: CME yields 3.7% and Tradeweb Markets 0.44%.
Tradeweb Markets scores higher on the StockData Score (17 against 9 for CME), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CME | TW |
|---|---|---|
| Size and price | ||
| Market cap | $109B | $28.7B |
| Share price | $303.14 | $122.54 |
| Change, 1 year | 15.9% | 16.2% |
| Change, 5 years | 36.7% | 29.7% |
| Beta (5Y) | 0.36 | 0.66 |
| Employees | 3,875 | 1,569 |
| StockData Score | ||
| Total score | 9 | 17 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 1 | 3 (better) |
| Performance score | 2 | 4 (better) |
| Health score | 5 | 5 |
| Dividend score | 1 | 2 (better) |
| Valuation | ||
| P/E | 25.7× (better) | 28.8× |
| P/S | 16.1× | 12.6× (better) |
| P/B | 4.1× (better) | 4.3× |
| EV/EBITDA | 24.2× | 21.8× (better) |
| P/FCF | 25.9× | 24.8× (better) |
| PEG | 1.75 | 0.78 (better) |
| FCF yield | 3.9% | 4.0% (better) |
| Fair value | $250.81 | $131.06 |
| Margin of safety | −20.9% | 6.5% (better) |
| Growth | ||
| Revenue growth (TTM) | 5.1% | 14.4% (better) |
| Revenue growth, 5Y average | 6.0% | 18.1% (better) |
| Net income growth (TTM) | – | 44.3% |
| EPS growth (TTM) | 14.1% | 45.9% (better) |
| EPS growth, 5Y average | 13.7% | 33.8% (better) |
| Profitability | ||
| Operating margin | 65.1% (better) | 44.1% |
| Net margin | – | 39.8% |
| FCF margin | 62.2% (better) | 50.6% |
| Return on equity | – | 14.1% |
| Return on invested capital | 13.5% | 17.7% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Interest coverage | – | 490× |
| Current ratio | 1.02 | – |
| Altman Z-score | 0.56 | 16.65 (better) |
| Piotroski F-score | 5 | 7 (better) |
| Dividends and buybacks | ||
| Dividend yield | 3.7% (better) | 0.44% |
| Years of dividend growth | 0 | 3 (better) |
| Dividend growth, 5Y average | −3.3% | 8.4% (better) |
| Buyback yield | – | 1.9% |
| Shareholder yield | 3.7% (better) | 2.4% |
| Ownership | ||
| Held by institutions | 89.5% | 50.0% |
| Held by insiders | 0.34% | 51.4% |
| Insider net buying, 12 months | −$30.4M (better) | −$44.6M |
| Superinvestors holding | 5 (better) | 2 |
| Short interest, % of float | 1.5% | 3.0% |
Go deeper
- CME stock overview
- CME income statement
- CME valuation and score
- TW stock overview
- TW income statement
- TW valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.